PEDIATRICS Vol. 99 No. 4 April 1997, pp. 575-580 (doi:10.1542/peds.99.4.575)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by King Jr, J. C.
Right arrow Articles by Lichenstein, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by King Jr, J. C.
Right arrow Articles by Lichenstein, R.
Related Collections
Right arrow Infectious Disease & Immunity

PEDIATRICS Vol. 99 No. 4 April 1997, pp. 575-580

Safety and Immunogenicity of Three Doses of a Five-Valent Pneumococcal Conjugate Vaccine in Children Younger Than Two Years With and Without Human Immunodeficiency Virus Infection

Received Jul 19, 1996; accepted Sep 13, 1996.

James C. King Jr, Peter E. Vink, John J. Farley, Martha Smilie, Marie Parks, and Richard Lichenstein

From the Department of Pediatrics, University of Maryland at Baltimore, School of Medicine, Baltimore, Maryland.

Objective.  To assess the safety and immunogenicity of three doses of a five-valent (types 6B, 23F, 14, 18C, and 19F) pneumococcal conjugate vaccine (PCV) among children younger than 2 years who are and are not infected with human immunodeficiency virus (HIV).

Methods.  A convenience sample of 18 HIV-infected children 2 years and younger (mean, 12.9 months) received three doses (each separated by 2 months) of PCV. An additional convenience sample of 33 non-HIV-infected children of virtually identical age, race, and sex as the HIV-infected group were randomized in a double-blind fashion to receive three doses of PCV or saline placebo. Safety data were collected for 72 hours after each vaccination. Sera were obtained before each and 1 month after the third vaccination to determine vaccine type-specific immunoglobulin G pneumococcal antibody titers by an enzyme-linked immunosorbent assay.

Results.  Seventeen HIV- and 30 non-HIV-infected children completed the study. The PCV was well tolerated by both HIV- and non-HIV-infected children. No significant differences in local or systemic reactions were noted between HIV- and non-HIV-infected PCV or placebo recipients. Three doses of PCV were immunogenic, as evidenced by 16- to 659-fold increases in type-specific geometric mean antibody titers over prevaccination levels in HIV- and non-HIV-infected children. With respect to an arbitrary protective level, 78% of the antibody titers from HIV-infected children and 88% of the titers from non-HIV-infected children were 1.0 µg/mL or greater 1 month after the third PCV dose. HIV-infected children with milder disease (Centers for Disease Control and Prevention classes N1-2, A1-2, and B1) were more likely to have protective antibody titers after the first and second PCV doses than HIV-infected children with more advanced disease (Centers for Disease Control and Prevention classes N3, A3, B2-3, and C1-3). However, after the third PCV dose, these differences disappeared.

Conclusion.  Three doses of PCV seem safe and immunogenic in both HIV- and non-HIV-infected children younger than 2 years. This type of vaccine should result in a marked reduction in systemic pneumococcal disease in both HIV- and non-HIV-infected children. Given the high incidence of invasive pneumococcal disease in HIV-infected children, this vaccine may markedly improve the quality of life for this unfortunate group of children.

Key words: pneumococcus, vaccine, human immunodeficiency virus, Streptococcus pneumoniae..




This article has been cited by other articles:


Home page
 CVIHome page
M. A. Rose, R. Schubert, N. Strnad, and S. Zielen
Priming of Immunological Memory by Pneumococcal Conjugate Vaccine in Children Unresponsive to 23-Valent Polysaccharide Pneumococcal Vaccine
Clin. Vaccine Immunol., October 1, 2005; 12(10): 1216 - 1222.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
S. A. Quataert, K. Rittenhouse-Olson, C. S. Kirch, B. Hu, S. Secor, N. Strong, and D. V. Madore
Assignment of Weight-Based Antibody Units for 13 Serotypes to a Human Antipneumococcal Standard Reference Serum, Lot 89-S(F)
Clin. Vaccine Immunol., November 1, 2004; 11(6): 1064 - 1069.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
K. L. O'Brien and M. Santosham
Potential Impact of Conjugate Pneumococcal Vaccines on Pediatric Pneumococcal Diseases
Am. J. Epidemiol., April 1, 2004; 159(7): 634 - 644.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
S. I. Pelton and J. O. Klein
The Future of Pneumococcal Conjugate Vaccines for Prevention of Pneumococcal Diseases in Infants and Children
Pediatrics, October 1, 2002; 110(4): 805 - 814.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
A Finn, R Booy, R Moxon, M Sharland, and P Heath
Should the new pneumococcal vaccine be used in high-risk children?
Arch. Dis. Child., July 1, 2002; 87(1): 18 - 21.
[Abstract] [Full Text] [PDF]

Home page
 Arch Pediatr Adolesc MedHome page
S. Bandyopadhyay, J. Bergholte, C. D. Blackwell, J. R. Friedlander, and H. Hennes
Risk of Serious Bacterial Infection in Children With Fever Without a Source in the Post-Haemophilus influenzae Era When Antibiotics Are Reserved for Culture-Proven Bacteremia
Arch Pediatr Adolesc Med, May 1, 2002; 156(5): 512 - 517.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
A. Ortqvist
Pneumococcal vaccination: current and future issues
Eur. Respir. J., July 1, 2001; 18(1): 184 - 195.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
S Choo and A Finn
Current topic: New pneumococcal vaccines for children
Arch. Dis. Child., April 1, 2001; 84(4): 289 - 294.
[Full Text]

Home page
 PediatricsHome page
G. D. Overturf, the Committee on Infectious Diseases, Committee on Infectious Diseases, 1999-2000, Ex-Officio, Liaisons, Consultant, and Staff
Technical Report: Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate and Polysaccharide Vaccines and Antibiotic Prophylaxis
Pediatrics, August 1, 2000; 106(2): 367 - 376.
[Abstract] [Full Text]